Although some studies have shown that PD-1 or PD-L1 monoclonal antibodies show good therapeutic prospects for some patients with advanced gastric cancer, most of the ineffective treatments limit their clinical application (Shitara et al., 2018; Song et al., 2020). Here, PDCD1 is linked to gastric cancer.